Bio-Rad Laboratories (NYSE:BIO.B) Issues Quarterly Earnings Results

Key Points

• Bio-Rad Laboratories reported a quarterly earnings per share of $2.61, with a return on equity of 4.04% and a net margin of 12.50%.
• The company's stock price remained flat at $247.05 during trading, with a market capitalization of $6.72 billion and a price-to-earnings ratio of 21.06.
• Bio-Rad operates in the life science and clinical diagnostics sectors, providing products used in research, biopharmaceuticals, and food testing across various regions.

Bio-Rad Laboratories (NYSE:BIO.B - Get Free Report) posted its earnings results on Thursday. The company reported $2.61 earnings per share (EPS) for the quarter, Zacks reports. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%.

Bio-Rad Laboratories Stock Performance

Bio-Rad Laboratories stock remained flat at $247.05 during mid-day trading on Wednesday. 14 shares of the company's stock were exchanged, compared to its average volume of 51. The company has a market capitalization of $6.72 billion, a price-to-earnings ratio of 21.06 and a beta of 0.76. The firm's fifty day moving average is $250.77 and its 200 day moving average is $266.20. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17. Bio-Rad Laboratories has a 1 year low of $225.29 and a 1 year high of $359.22.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.